Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Amgen Inc.NASDAQ: AMGN

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $2.38B rose 65.9% year over year, ahead of the +32.1% change in trailing-twelve-month net income. Sequentially, it rose 30.6% from the prior quarter. Over 3 fiscal years it compounded at +5.6% a year.

Context

  • Net income amounted to 21.0% of revenue in FY2025, up 8.8 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 22 analysts of $12.78B (+65.7%) for the fiscal year ending Dec 2026, a slowdown from the +88.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.38B+30.6% QoQ
Last fiscal yearDec 2025
$7.71B+88.5% YoY
LTMJun 2026
$8.74B+32.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+65.9%-1.8%-67.6 pp
1 year+88.5%+65.7%-22.8 pp
3-year CAGR+5.6%+23.4%+17.9 pp
5-year CAGR+17.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
7.71B USD
Year-over-year change
+88.5%
4-year CAGR
+7.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How AMGN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +32.1% is the 5th highest of 10, against a peer median of +15.4%.
  • Net income amounts to 22.9% of revenue for AMGN, versus a peer median of 16.9%.
AMGN Competitors
Net Income for AMGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.4%+32.5%22.9%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$9.27B USD+83.1%+3.6%18.9%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
ABBVAbbVie Inc.LTM Jun 2026$6.32B USD+66.4%-29.1%9.8%
GSKGSK plcLTM Jun 2026£5.62B GBP+41.0%+0.6%16.9%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding AMGN) —+15.4%+7.9%16.9%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income5.89B6.55B6.72B4.09B7.71B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
Deferred Income Tax(453M)(1.2B)(1.27B)(1.23B)(721M)
Stock-Based Compensation341M401M431M530M494M
Change in Working Capital(1.19B)(733M)(484M)2.37B(1.98B)
Accounts Receivables(429M)(746M)(1.02B)441M(2.68B)
Inventory(165M)(742M)491M2.53B886M
Accounts Payables(69M)154M(402M)312M428M
Other Working Capital(531M)601M442M(920M)(616M)
Other Non-Cash Items1.28B1.28B(991M)141M(715M)
Operating Cash Flow9.26B9.72B8.47B11.49B9.96B
Capital Expenditures(880M)(936M)(1.11B)(1.1B)(1.86B)
Acquisitions (Net)(2.69B)(3.73B)(26.99B)0(53M)
Purchases of Investments(8.9B)(2.59B)(1M)00
Sales of Investments13.23B1.22B1.67B00
Other Investing Activities(35M)(12M)225M50M(32M)
Investing Cash Flow733M(6.04B)(26.2B)(1.05B)(1.94B)
Debt Repayment795M6.62B25.68B(4.26B)(5.68B)
Common Stock Issued00000
Common Stock Repurchased(4.98B)(6.36B)0(200M)0
Dividends Paid(4.01B)(4.2B)(4.56B)(4.83B)(5.12B)
Other Financing Activities(78M)(103M)(72M)(124M)(52M)
Financing Cash Flow(8.27B)(4.04B)21.05B(9.42B)(10.86B)
Effect of Forex Changes00000
Net Change in Cash1.72B(360M)3.32B1.03B(2.84B)
Free Cash Flow8.38B8.79B7.36B10.39B8.1B

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.